COMPARISON OF PROTECTIVE EFFECT OF NEUTRALIZING ANTIBODY IN SERUM AND NASAL SECRETIONS IN EXPERIMENTAL RHINOVIRUS TYPE 13 ILLNESS

Perkins, J. C. (NIAID, NIH, Bethesda, Md. 20014), D. N. Tucker, H.L.S. Knopf, R. P. Wenzel, A. Z. Kapikian and R. M. Chanock. Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness. Amer. J. Epid., 1969, 90: 519–526.—An inactivated rhinovirus type 13 vaccine was administered to adult male volunteers by the intramuscular (IM) or intranasal (IN) route. When the men were challenged with approximately 100 TCD50 of type 13 virus, a significant protective effect was seen in individuals given vaccine IN, whereas the frequency with which illness developed in IM vaccinees did not differ from that of the seronegative controls. The volunteers who received the vaccine IN developed both serum and nasal secretory antibodies, while the volunteers who were vaccinated IM developed primarily a serum antibody response. When the response to challenge of the vaccinees was evaluated according to level of serum or nasal antibody, only nasal secretory antibody was associated with resistance to infection and illness.